Featured news from NHIVNA
HIV-related news from NAM
Injectable cabotegravir plus rilpivirine every two months maintains viral suppression for three years, but carries higher risk of treatment failure
Mercy Shibemba, 1970-01-01 12:00:00
Source:aidsmap.com
